-
PROVIDERS
Now Available: xT CDx, FDA-Approved Assay
Discover xT CDx, the FDA-approved assay delivering comprehensive insights through tumor + normal DNA sequencing
-
LIFE SCIENCES
ENROLL NOW
Tempus 3D Tumor Organoid (TO) Screen Evaluate the efficacy of preclinical compounds, including small molecules, monoclonal antibodies (mAbs), peptides, and ADCs. Space is limited—enroll by March 31, 2025, to secure your spot.
-
PATIENTS
It's About Time
View the Tempus vision.
- RESOURCES
-
ABOUT US
View Job Postings
We’re looking for people who can change the world.
- INVESTORS
10/10/2024
Washington University
Researchers from Tempus partnered with Washington University School of Medicine to study the association between germline alterations in cancer-predisposition genes across lung cancer patients.
Historically, the understanding of the molecular features of lung cancer has been derived primarily from a limited approach focussed on analysis of biopsies from smokers. Few studies have identified the underlying genetic alterations linked to ancestry, smoking status, and tumor characterization. This project aims to gain a broad understanding of these germline features and how they are linked to tumor location and presentation.
This study was presented at the ASCO Annual Meeting in June 2023.
-
02/13/2025AI & ML in action: Real-time advances in precision medicine
Explore the capabilities of the Tempus platform, where cutting-edge diagnostics meet actionable data insights to enhance precision medicine. Learn how AI and ML tools seamlessly integrate biomarkers into the diagnostic process, ensuring patients receive the right treatment(s) at the right time. Experience Tempus Lens in action, with an exclusive live demonstration of our newest AI advancements, and hear perspectives on AI's expanding role in healthcare and its transformative potential.
Watch replay -
01/27/2025Addressing health disparities at a large academic medical center: AI-driven cardiac care for aortic stenosis and mitral regurgitation
Leveraging a natural language processing (NLP) based, artificial intelligence (AI) driven protocol, Tempus Next worked to help clinicians improve management of patients with severe aortic stenosis (sAS) and severe mitral regurgitation (sMR) by identifying patients who may have been previously overlooked.
Read more -
12/05/2024
Advancing IO therapeutics: The convergence of novel biomarkers and combination strategies
Explore the latest in immuno-oncology (IO), where emerging therapies are reshaping the landscape of cancer treatment. This webinar will focus on the role of novel biomarkers and combination treatment strategies in understanding and enhancing the immune system's response to cancer. Discover the significant developments that are helping to shape clinical trials and improving patient outcomes in IO and hear perspectives from industry experts on the potential of emerging therapies.
Watch replay